Dose conversion ratio, comparative efficacy, and adverse events after switching from onabotulinum toxin A to abobotulinum toxin A for neurological conditions

Ozer, İNCİ; Kumcu, Muge; Aydemir, Sabiha; AKBOSTANCI, MUHİTTİN

doi:10.1016/j.clineuro.2021.106889

Dose conversion ratio, comparative efficacy, and adverse events after switching from onabotulinum toxin A to abobotulinum toxin A for neurological conditions

Ozer İ. Ş., Kumcu M. K., Aydemir S. T., AKBOSTANCI M. C.

CLINICAL NEUROLOGY AND NEUROSURGERY, cilt.209, 2021 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 209
Basım Tarihi: 2021
Doi Numarası: 10.1016/j.clineuro.2021.106889
Dergi Adı: CLINICAL NEUROLOGY AND NEUROSURGERY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE
Anahtar Kelimeler: Abobotulinum toxin A, Onabotulinum toxin A, Dystonia, Dysport, Botox, Dose conversion ratio
Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Objectives: Onabotulinum toxin A (ONA, Botox (R)) and abobotulinum toxin A (ABO, Dysport (R)) are most frequently used in the treatment of movement disorders. The aim of this study was to identify the dose conversion ratio (ABO dose:ONA dose), comparative efficacy, and adverse events in patients who switched from ONA to ABO.